AIM ImmunoTech Inc. has announced that the NYSE Regulation has lifted the trading suspension of the Company's common stock on the NYSE American. The suspension was initially due to low selling price issues, but the stock is now trading above the required threshold. AIM's common stock is expected to resume trading on June 17, 2025, under the symbol "AIM."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.